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Abstract
Background:  Not only the prevalence, but also the progress of metabolic abnormalities in
schizophrenic patients is of importance for treatment planning and policy making. However, there
have been very few prospective studies of metabolic disturbance in schizophrenic patients. This
study aimed to assess the progress of metabolic abnormalities in Thai individuals with schizophrenia
by estimating their one-year incidence rate of metabolic syndrome (MetS).
Methods: We screened all schizophrenic patients who visited our psychiatric clinic. After the
exclusion of participants with MetS at baseline, each subject was reassessed at 6 and 12 months to
determine the occurrence of MetS. The definition of MetS, as proposed by the International
Diabetes Federation (IDF), was applied.
Results: Fifty-seven participants (24 males and 33 females) had a mean of age and duration of
antipsychotic treatment of 37.5 years old and 8.4 years, respectively. At baseline, 13 subjects met
the MetS definition. Of 44 subjects who had no MetS at baseline, 35 could be followed up. Seven
of these 35 subjects (20.0%) had developed MetS at the 6- or 12-month visit, after already having
2 MetS components at baseline. The demographic data and characteristics of those developing and
not developing MetS were not different in any respect.
Conclusion: Thai schizophrenic patients are likely to develop MetS. Their metabolic abnormalities
may progress rapidly and fulfill the MetS definition within a year of follow-up. These findings support
the importance of assessing and monitoring metabolic syndrome in schizophrenic patients.
Background
During the last several years, there has been a growing
interest in metabolic abnormalities in the general popula-
tion and schizophrenic patients. These disturbances are
highly coincident and called metabolic syndrome (MetS),
which is a cluster of risk factors for cardiovascular disease
comprising central obesity, dyslipidemia, hypertension,
and elevated fasting plasma glucose (FPG) level. The
results of a recent meta-analysis of 21 studies showed that
individuals with the MetS, compared to those without,
had an increased mortality from all causes (relative risk
[RR] 1.35; 95% confidence interval [CI], 1.17–1.56) and
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cardiovascular disease (RR 1.74; 95% CI, 1.29–2.35); as
well as an increased incidence of cardiovascular disease
(RR 1.53; 95% CI, 1.26–1.87), coronary heart disease (RR
1.52; 95% CI, 1.37–1.69) and stroke (RR 1.76; 95% CI,
1.37–2.25) [1].
There has been a number of MetS definitions presented
over the last decade. The widely accepted ones are those
proposed by i) National Cholesterol Education Program
Adult Treatment Panel III (ATP III) [2]; ii) American Heart
Association/National Heart, Lung, and Blood Institute,
AHA/NHLBI (updated ATP III) [3]; and iii) International
Diabetes Federation (IDF) [4]. Table 1 shows the similar-
ities and differences among these definitions. A major dif-
ference between the ATP and IDF diagnostic systems is the
necessity of central obesity for making a diagnosis. While
the updated ATP III definition requires any three of five
criteria for a diagnosis, the IDF definition needs central
obesity plus any other two abnormalities. Despite this dif-
ference, updated ATP III and IDF criteria still identify
essentially the same individuals as having MetS. In addi-
tion, recommendations for clinical management are virtu-
ally identical in the updated ATP III and IDF reports [3].
Depending on the various definitions used, prevalence
studies of MetS in large sample sizes of schizophrenic
patients showed rates of between 28.4% and 44.7%. In
240 Canadian subjects with schizophrenia or schizoaffec-
tive disorder, 44.7% of them met the ATP III diagnosis of
MetS [5]. Both the original and updated ATP III defini-
tions were applied in 689 Americans with schizophrenia,
who participated in the Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) Schizophrenia Trial.
The prevalence rates of MetS in the CATIE study were
40.9% (ATP III) and 42.7% (updated ATP III) [6]. A more
recent study in 430 Belgian subjects with schizophrenia
showed a prevalence of 28.4% (ATP III), 32.3% (updated
ATP III), and 36% (IDF) [7].
While the prevalence of MetS in schizophrenic patients is
approximately two to four times higher than that in the
general population [6,8], people with MetS are twice as
likely to die from it and three times more likely to have a
heart attack or stroke compared to people without it [9],
These findings are in concordance with the fact that cardi-
ovascular disease ranks high among the natural causes of
death in the schizophrenia population [10,11].
There has been very little evidence about the prevalence of
MetS in Thai people. The limited data have shown that
18.5%–26.5% of Thai people may have ATP III MetS in
comparison to 30.9%–35.3% of the US population [2].
To our knowledge, there has been no prevalence study of
MetS in any Asian psychotic population.
Not only the prevalence, but also the progress of meta-
bolic abnormalities in schizophrenic patients is of impor-
tance for treatment planning and policy making.
However, there have been very few prospective studies of
metabolic disturbance in schizophrenic patients. We,
therefore, proposed an assessment of metabolic abnor-
mality progress in Thai individuals with schizophrenia by
conducting a one-year prospective study of MetS in this
population.
Methods
Study location
We carried out this study at a psychiatric clinic in Chiang
Mai University Hospital, Chiang Mai, Thailand; a general
hospital providing tertiary care for people in northern
Table 1: ATPIII, Updated ATP III, and IDF definitions of metabolic syndrome [2-4]
ATP III (2000) Updated ATP III (2004) IDF (2005)
Elevated waist circumference Male ≥ 102 cm; 
Female ≥ 88 cm
Male ≥ 102 cm; 
Female ≥ 88 cm
for Caucasians
Male ≥ 90 cm; 
Female ≥ 80 cm for Asian Americans
Male ≥ 90 cm; 
Female ≥ 80 cm
for South Asians/Chinese
Elevated triglycerides ≥150 mg/dL ≥150 mg/dL or receiving drug treatment
Decreased high-density lipoprotein cholesterol Male <40 mg/dL; 
Female <50 mg/dL
Male <40 mg/dL; Female <50 mg/dL or receiving drug treatment
Elevated blood pressure ≥130/≥85 mm Hg ≥130/≥85 mm Hg or receiving drug treatment
Elevated fasting plasma glucose ≥110 mg/dL ≥100 mg/dL or receiving drug treatmentBMC Psychiatry 2007, 7:14 http://www.biomedcentral.com/1471-244X/7/14
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Thailand. The study was approved by the Ethics Commit-
tee for Research, Faculty of Medicine, Chiang Mai Univer-
sity, under the condition that both the subjects and their
first degree relatives had given written informed consent
prior to study participation.
Subjects and criteria
We screened all DSM-IV schizophrenic patients, who vis-
ited the psychiatric clinic, for their eligibility to participate
in the study. The inclusion criteria were patients aged 18
years old or more, who had taken antipsychotics for at
least three months.
This study excluded schizophrenic patients who took
medications for metabolic abnormalities. Recent findings
have shown that new and emerging drug therapies for an
individual component of MetS may affect others. While
an antiobesity agent may reduce atherogenic dyslipidemia
and abnormal glucose metabolism [12], many conven-
tional antihypertensive drugs influence the development
of new onset diabetes, both positively and negatively [13].
The inclusion of a patient receiving treatment for MetS or
its component into a prospective study may therefore
have an impact on the chance of developing other meta-
bolic abnormalities.
Other exclusion criteria were i) hospitalization due to
physical illnesses during 1 month prior to the visit, ii)
pregnancy, and iii) regular renal hemodialysis.
Assessment and outcomes
To assess the blood levels of triglycerides, HDL-choles-
terol, and FPG, each subject had to fast himself/herself
after midnight and have a blood test between 8 am and 10
am on the assessment day. Body weight was measured
digitally with the subject wearing light cloth and no shoes.
Waist circumference was measured in a horizontal plane,
midpoint between the inferior margin of the ribs and the
superior border of the iliac crest. Sitting blood pressure
was measured digitally twice, and the mean reading was
used.
All subjects received metabolic reassessment at 6 (range
5–7) months and 12 (range 11–13) months. Anyone who
missed the 6-month assessment was still allowed to have
a 12-month evaluation.
Only the IDF definition was applied to this study. This
decision was made because the IDF is more purposefully
developed for worldwide use than the updated ATP IIII.
The IDF clearly defines the waist circumference cut points
applied for South Asian/Chinese men and women living
in Asia, who are closely related to Thais both ethnically
and environmentally. The updated ATP III definition was
not concurrently used because, as mentioned above, this
diagnostic system is almost identical to the IDF one.
We clearly informed all subjects about the results of their
metabolic assessment. For those who were found to have
metabolic abnormalities, we gave them advice on a
healthy lifestyle, including, moderate calorie restriction,
moderate increase in physical activity and change in die-
tary composition. In addition, we encouraged them to
report their metabolic results to their psychiatrists.
Statistical analyses
The percentage of subjects who developed MetS was calcu-
lated. For the risk assessment, significant differences in
proportions were determined by using Fisher's exact tests,
and mean differences were assessed by using the Student-
t tests. The p-values were two-tailed, and the term statisti-
cally significant applied to a p-value of < 0.05.
Results
Characteristics of the participants
Eighty-eight schizophrenic patients visited the clinic
between February and August 2004. Twenty-five (28.4%)
were excluded due to no consent given by the patients
themselves and/or their 1st degree relatives, and 6 (6.8%)
because medications for metabolic disturbances had been
taken. Fifty-seven patients (24 men and 33 women) par-
ticipated in the study, with a mean ± SD age and duration
of antipsychotic treatment of 37.5 ± 12.7 years old and 8.4
± 6.3 years, respectively.
At baseline, 13 of the 57 participants (22.8%) fulfilled the
MetS definition and were therefore excluded from the
incidence analysis. Table 2 shows the demographic data
and characteristics of all 57 subjects participating in the
study, and the 44 subjects included in the incidence study.
Dropouts and the antipsychotics used
Of 44 subjects included in the incidence study, 9 (20.5%)
were lost to follow-up. The demographic data and charac-
teristics of the 35 subjects who completed the study were
not significantly different from those of the 44 subjects
included in the incidence study (see Table 2). At the end
of a 1-year study, the number of subjects taking high-
potency conventional antipsychotics was smaller, but that
of participants receiving sertindole was larger. Table 3
shows the details of antipsychotic medications used at
baseline and endpoint.
Incidence analysis
Although the 44 subjects included in the analysis did not
meet the definition at baseline, 16 of them had 1 compo-
nent, 15 had 2 components, and 3 had 3 components.
Only 10 of them (22.7%) had no metabolic abnormality
defined by the IDF. Seven of the 35 subjects (20.0%) thatBMC Psychiatry 2007, 7:14 http://www.biomedcentral.com/1471-244X/7/14
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Table 2: Demographic data and characteristics of the subjects in total, including those in the incidence study, and those who 
completed the incidence studya, b
Total participants 
(N = 57)
Subjects included 
the study (N = 44)
Subjects completed 
the study (N = 35)
Number of male patients 24 (42.1) 18 (40.9) 13 (37.1)
Age, years 37.5 ± 12.7 35.5 ± 11.9 34.7 ± 11.2
Age at schizophrenia onset, years 28.5 ± 11.9 26.8 ± 11.1 26.0 ± 10.3
Duration of antipsychotic treatment 8.4 ± 6.3 8.2 ± 6.5 8.1 ± 6.3
Number of hospitalizations 1.8 ± 2.2 1.8 ± 2.5 1.6 ± 2.3
Patients taking second-generation antipsychoticsc (including, clozapine, 
olanzapine, risperidone, and sertindole)
33 (57.9) 24 (54.5) 19 (54.3)
Patients reporting metabolic disturbances in their 1st degree relatives
1. Obesity 6 (10.5) 5 (11.4) 3 (8.6)
2. Dyslipidemia 5 (8.8) 4 (9.1) 3 (8.6)
3. Hypertension 20 (35.1) 15 (34.1) 13 (37.1)
4. Diabetes mellitus 8 (14.0) 6 (13.6) 4 (11.4)
Patients with cluster diseases of MetS
1. Obesity (BMI ≥ 30 kg/m2) 4 (7.0) 2 (4.5) 2 (5.7)
2. Central obesity (waist circumference ≥ 90 cm for men or ≥ 80 cm 
for women)
27 (47.4) 14 (31.8) 11 (31.4)
3. High triglyceride level (≥ 150 mg/dL) 22 (38.6) 12 (27.3) 10 (28.6)
4. Low HDL cholesterol level (<40 mg/dL for men or <50 mg/dL for 
women)
16 (28.1) 10 (22.7) 8 (22.9)
5. High blood pressure (≥ 130/≥ 85 mm Hg) 17 (29.8) 11 (25.0) 8 (22.9)
6. High fasting glucose level (≥ 100 mg/dL) 16 (28.1) 8 (18.2) 6 (17.1)
aData shown as mean ± SD and N (%)
bNo significant difference (p > 0.05) for all comparisons.
cThe rest were taking first-generation antipsychotics.
Abbreviation: BMI = body mass index, HDL = high-density lipoprotein.
Table 3: Antipsychotics taken by subjects including those in the incidence study at baseline and endpoint
Medications Number (%) of subjects taking at 
baseline (N = 44)
Number of subjects lost to 
follow-up (N = 9)
Number (%) of subjects taking 
at endpoint (N = 35)a
High-potency conventional 
antipsychoticsb
12 (27.3) 2 4 (11.4)
Medium-potency conventional 
antipsychoticsc
4 (9.1) 1 4 (11.4)
Low-potency conventional 
antipsychoticsd
5 (11.4) 2 5 (14.3)
Clozapine 5 (11.4) 2 7 (20.0)
Olanzapine 3 (6.8) 1 5 (14.3)
Risperidone 14 (31.8) 1 13 (37.1)
Sertindole 1 (2.3) 0 12 (34.3)
aIncluding 7 patients developing metabolic syndrome and 28 patients not developing metabolic syndrome.
bHigh-potency conventional antipsychotics including haloperidol and trifluoperazine.
cMedium-potency conventional antipsychotics including clopenthixol and perphenazine.
dLow-potency conventional antipsychotics including chlorpromazine and thioridazine.BMC Psychiatry 2007, 7:14 http://www.biomedcentral.com/1471-244X/7/14
Page 5 of 6
(page number not for citation purposes)
could be followed up for one year developed IDF MetS.
All 7 subjects who developed IDF MetS were those who
already had 2 components at baseline.
Risks of MetS
There was no significant difference between the 7 subjects
who developed MetS and the 28 subjects who did not in
respect of sex, age, age at schizophrenia onset, duration of
antipsychotic treatment, number of hospitalizations, and
self-reported family history of obesity, dyslipidemia,
hypertension, and diabetes mellitus (see Table 4).
Discussion
This study found that 20.0% of Thai schizophrenic
patients receiving long-term antipsychotic treatment
developed MetS within a year of follow-up. However, no
risk factor for its development could be found.
By applying the IDF MetS definition, metabolic abnor-
malities were very common in these Thai schizophrenic
patients. After the exclusion of those receiving treatment
for metabolic disturbances at baseline, 47 of 57 subjects
(82.5%) included in this study still had metabolic abnor-
malities. Another interesting result was that all 7 subjects
who developed MetS within the 12 months follow-up
were part of the 15 participants who already had 2 MetS
components at baseline. This finding may suggest that, for
schizophrenic patients who have 2 MetS conditions,
almost half of them may fulfill the MetS definition within
a year.
To our knowledge, there has been no incidence study of
MetS in schizophrenia patients. However, in comparison
to the 3-year incidence rate of ATP III MetS in the general
population in France (8.0%–10.5%) [14], our subjects
may be more likely to develop MetS than the general pop-
ulation. However, due to ethnic and illness differences,
this comparison should be viewed with great caution.
In this study, selection bias, a common problem found in
epidemiological studies, was minimized by including all
patients who visited our clinic. However, the switching of
conventional antipsychotic medications to atypical ones
in a large proportion of subjects may be the most impor-
tant limitation of this study. Because some atypical antip-
sychotic agents have a worse metabolic profile than the
conventional ones [15], the high rate of antipsychotic
switching may directly influence the new-onset MetS in
many studied subjects. In contrast, the interventions for
metabolic abnormalities given during the study probably
lower the actual rate of the incidence. Other limitations of
this study include the exclusion of older patients with
MetS at baseline, a large proportion of excluded patients,
a small sample size, the lack of a control group, and a high
drop-out rate.
The findings of this study may not be able to generalize in
other ethnic groups. The differential prevalence of MetS
across ethnic groups has been found in the general popu-
lation [16] and schizophrenic patients [17]. It is therefore
possible that the incidence rates of MetS also vary among
ethnic groups with schizophrenia.
Table 4: Comparison the characteristics of patients developing and not developing MetSa
Patients developing MetS 
(N = 7)
Patients not developing MetS 
(N = 28)
Significant difference
Number of male patients 3 (42.9) 9 (32.1) Fisher's exact test, 
p = .68
Age, years 38.7 ± 12.9 35.3 ± 11.4 t = .69, df = 32, 
p = .49
Age at schizophrenia onset, years 27.0 ± 15.1 26.3 ± 8.8 t = .15, df = 32, 
p = .88
Duration of antipsychotic treatment 11.6 ± 8.7 8.1 ± 6.0 t = 1.25, df = 32, 
p = .22
Number of hospitalizations 2.1 ± 1.7 1.9 ± 3.0 t = .18, df = 32, 
p = -.86
Patients reporting metabolic disturbances in their 1st degree 
relatives
1. Obesity 1 (14.9) 2 (7.1) Fisher's exact test,
p = .51
2. Dyslipidemia 0 (0.0) 3 (10.7) Fisher's exact test, 
p = 1.00
3. Hypertension 3 (42.9) 10 (35.7) Fisher's exact test, 
p = .68
4. Diabetes mellitus 0 (0.0) 4 (14.3) Fisher's exact test, 
p = .56
aData shown as mean ± SD and N (%)
Abbreviation: MetS = metabolic syndrome.BMC Psychiatry 2007, 7:14 http://www.biomedcentral.com/1471-244X/7/14
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Conclusion
Thai schizophrenic patients receiving long-term antipsy-
chotic treatment are likely to have metabolic abnormali-
ties. These abnormalities may rapidly progress and fulfill
the MetS definition within years of follow-up. These find-
ings support the importance of assessing and monitoring
metabolic parameters in schizophrenic patients, as pro-
posed recently [18,19].
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